<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Secondary <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> (PTC) in pediatric <z:hpo ids='HP_0002664'>oncology</z:hpo> and hematology is an unpredictable and under-recognized condition </plain></SENT>
<SENT sid="1" pm="."><plain>It is characterized by increased cerebrospinal fluid (CSF) pressure of more than 25 cm <z:chebi fb="0" ids="15377">H(2)O</z:chebi> in the absence of underlying structural causes </plain></SENT>
<SENT sid="2" pm="."><plain>Numerous conditions and medications have been implicated in the etiology of secondary PTC </plain></SENT>
<SENT sid="3" pm="."><plain>Patients may suffer from incapacitating <z:hpo ids='HP_0002315'>headaches</z:hpo> and permanent <z:hpo ids='HP_0000572'>visual loss</z:hpo>, if they are not managed properly </plain></SENT>
<SENT sid="4" pm="."><plain>We retrospectively analyzed the records of eight children, diagnosed with secondary PTC with an underlying hematological or oncological disease </plain></SENT>
<SENT sid="5" pm="."><plain>Our study highlights the clinical features, contributing factors, and treatment options of this syndrome in children </plain></SENT>
</text></document>